B of A Securities analyst Graham Perry downgrades Novartis (NYSE:NVS) from Buy to Neutral and lowers the price target from $135 to $130.
B of A Securities Downgrades Novartis to Neutral, Lowers Price Target to $130
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.